EPISODE · Jul 30, 2025 · 11 MIN
Background of ICI & Highlights in Oncology
from Conversations With Cancer Experts About Novel Delivery Options With Checkpoint Inhibitors (ICIs) · host Annenberg Center for Health Sciences
Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 yearsMultiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011Robust survival benefit seen with ICI across multiple tumor typesIV ICI therapy requires line access and creates increased chair timeSubcutaneous (SC) ICI options provide increased patient convenience and operational efficienciesSC products may increase nurse resources due to time spent administering
What this episode covers
Immune-checkpoint inhibitors (ICIs) represent a significant breakthrough in the field of cancer over the last 10-15 yearsMultiple ICIs currently available as IV therapies (8 PD-1/PD-L1 agents approved since 2011Robust survival benefit seen with ICI across multiple tumor typesIV ICI therapy requires line access and creates increased chair timeSubcutaneous (SC) ICI options provide increased patient convenience and operational efficienciesSC products may increase nurse resources due to time spent administering
NOW PLAYING
Background of ICI & Highlights in Oncology
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m